NewDEL Biotech Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Series A1
- Investors
-
9
NewDEL Biotech General Information
Description
Developer of innovative drugs designed for tumors. The company offers DNA Encoded Library technology to significantly improve the success rate of drugs, thereby enabling tumor patients to have next-generation alternative medicines.
Contact Information
Website
www.newdel.com.cnCorporate Office
- Unit 9-5, Building T1, Chuanyiyuan, Number 4 Guanhe Road, Junzibu Community
- Guanlan Subdistrict, Longhua District
- Shenzhen, Guangdong 518110
- China
Corporate Office
- Unit 9-5, Building T1, Chuanyiyuan, Number 4 Guanhe Road, Junzibu Community
- Guanlan Subdistrict, Longhua District
- Shenzhen, Guangdong 518110
- China
NewDEL Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Early Stage VC (Series A1) | 21-Jan-2026 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A1) | 12-Mar-2025 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 11-Mar-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 28-Jul-2023 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 01-Jun-2022 | Completed | Generating Revenue | |||
| 2. Seed Round | 17-Jul-2021 | Completed | Startup | |||
| 1. Accelerator/Incubator | 28-Apr-2021 | Completed | Startup |
NewDEL Biotech Patents
NewDEL Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025040141-A1 | Use of compound 1 in treating or preventing disease associated with c-kit mutation or c-kit fusion mutation | Inactive | 23-Aug-2023 | ||
| JP-2026527881-A | Use of compound 1 in the treatment or prevention of diseases associated with ret fusion and/or ret mutations | Pending | 01-Jul-2023 | ||
| EP-4734998-A1 | Use of compound 1 in treatment or prevention of disease related to ret fusion and/or ret mutation | Pending | 01-Jul-2023 | ||
| EP-4734998-A4 | Use of compound 1 in treatment or prevention of disease related to ret fusion and/or ret mutation | Pending | 01-Jul-2023 | ||
| WO-2025007816-A1 | Use of compound 1 in treatment or prevention of disease related to ret fusion and/or ret mutation | Inactive | 01-Jul-2023 | C07D487/04 |
NewDEL Biotech Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| XtalPi Technology | Corporation | Minority | ||
| Tsingda Venture Capital | PE/Buyout | Minority | ||
| Shenzhen High-Tech Investment | Venture Capital | Minority | ||
| Zhuhai Hecheng Zhiyi Capital Management | Growth/Expansion | Minority | ||
| Bangqin Capital | Venture Capital | Minority |
NewDEL Biotech FAQs
-
When was NewDEL Biotech founded?
NewDEL Biotech was founded in 2021.
-
Where is NewDEL Biotech headquartered?
NewDEL Biotech is headquartered in Shenzhen, China.
-
What industry is NewDEL Biotech in?
NewDEL Biotech’s primary industry is Drug Discovery.
-
Is NewDEL Biotech a private or public company?
NewDEL Biotech is a Private company.
-
What is NewDEL Biotech’s current revenue?
The current revenue for NewDEL Biotech is .
-
Who are NewDEL Biotech’s investors?
XtalPi Technology, Tsingda Venture Capital, Shenzhen High-Tech Investment, Zhuhai Hecheng Zhiyi Capital Management, and Bangqin Capital are 5 of 9 investors who have invested in NewDEL Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process